---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-029174"
form_type: "8-K"
ticker: "IMMX"
cik: "0001873835"
company_name: "Immix Biopharma, Inc."
filed_at: "2024-07-26T23:59:59+00:00"
generated_at: "2026-05-31T16:01:35.158508+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immix Biopharma subsidiary Nexcella awarded $8M CIRM grant for NXC-201 AL Amyloidosis trial

## Summary
- $8 million CLIN2 grant from California Institute for Regenerative Medicine to support NXC-201 CAR-T therapy for relapsed/refractory AL Amyloidosis.
- NEXICART-2 U.S. Phase 1b/2 trial to evaluate NXC-201; builds on prior ex-U.S. data showing 92% overall response rate.
- NXC-201 is the only CAR-T therapy in development for AL Amyloidosis and has Orphan Drug Designation from FDA and EMA.
- No FDA approved drugs currently for relapsed/refractory AL Amyloidosis; CIRM grant adds non-dilutive funding to ongoing clinical program.

## SEC filing metadata
- accession: 0001493152-24-029174
- form_type: 8-K
- ticker: IMMX
- cik: 0001873835
- company_name: Immix Biopharma, Inc.
- filed_at: 2024-07-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873835/000149315224029174/0001493152-24-029174-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873835/000149315224029174/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-029174
- JSON: https://secwatch.observer/filing/0001493152-24-029174.json
- Plain text: https://secwatch.observer/filing/0001493152-24-029174.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.